Somatropin - Genentech/Alkermes

Drug Profile

Somatropin - Genentech/Alkermes

Alternative Names: Nutropin Depot; Somatropin ProLease

Latest Information Update: 21 Sep 2004

Price : $50

At a glance

  • Originator Alkermes; Genentech
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Somatotropin deficiency

Most Recent Events

  • 16 Jul 2013 Biomarkers information updated
  • 21 Sep 2004 A clinical study has been added to the pharmacokinetics section
  • 03 Jun 2004 Withdrawn for Somatotropin deficiency in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top